TVTX logo

Travere Therapeutics, Inc. (TVTX) Cash From Operations

Annual CFO:

-$237.47M+$42.55M(+15.19%)
December 31, 2024

Summary

  • As of today, TVTX annual cash from operations is -$237.47 million, with the most recent change of +$42.55 million (+15.19%) on December 31, 2024.
  • During the last 3 years, TVTX annual cash from operations has fallen by -$222.68 million (-1505.43%).
  • TVTX annual cash from operations is now -3307.82% below its all-time high of $7.40 million, reached on December 31, 2017.

Performance

TVTX Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXcash flow metrics

Quarterly CFO:

$4.98M+$47.18M(+111.81%)
June 30, 2025

Summary

  • As of today, TVTX quarterly cash from operations is $4.98 million, with the most recent change of +$47.18 million (+111.81%) on June 30, 2025.
  • Over the past year, TVTX quarterly cash from operations has increased by +$45.23 million (+112.38%).
  • TVTX quarterly cash from operations is now -84.46% below its all-time high of $32.06 million, reached on September 30, 2021.

Performance

TVTX Quarterly Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXcash flow metrics

TTM CFO:

-$115.44M+$45.23M(+28.15%)
June 30, 2025

Summary

  • As of today, TVTX TTM cash from operations is -$115.44 million, with the most recent change of +$45.23 million (+28.15%) on June 30, 2025.
  • Over the past year, TVTX TTM cash from operations has increased by +$173.42 million (+60.04%).
  • TVTX TTM cash from operations is now -1659.34% below its all-time high of $7.40 million, reached on December 31, 2017.

Performance

TVTX TTM Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXcash flow metrics

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

TVTX Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+15.2%+112.4%+60.0%
3Y3 Years-1505.4%+113.5%-32.8%
5Y5 Years-307.9%+177.2%-246.0%

TVTX Cash From Operations Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-1505.4%+15.2%at high+104.2%at high+63.7%
5Y5-Year-1505.4%+15.2%-84.5%+104.2%-6367.1%+63.7%
All-TimeAll-Time-3307.8%+15.2%-84.5%+104.2%-1659.3%+63.7%

TVTX Cash From Operations History

DateAnnualQuarterlyTTM
Jun 2025
-
$4.98M(+111.8%)
-$115.44M(+28.1%)
Mar 2025
-
-$42.19M(-18.1%)
-$160.66M(+32.3%)
Dec 2024
-$237.47M(+15.2%)
-$35.72M(+16.0%)
-$237.47M(+12.8%)
Sep 2024
-
-$42.51M(-5.6%)
-$272.23M(+5.8%)
Jun 2024
-
-$40.24M(+66.2%)
-$288.86M(+9.1%)
Mar 2024
-
-$119.00M(-68.9%)
-$317.91M(-13.5%)
Dec 2023
-$280.02M(-50.3%)
-$70.47M(-19.2%)
-$280.02M(-6.0%)
Sep 2023
-
-$59.13M(+14.7%)
-$264.19M(-8.0%)
Jun 2023
-
-$69.30M(+14.6%)
-$244.58M(-15.3%)
Mar 2023
-
-$81.12M(-48.5%)
-$212.09M(-13.8%)
Dec 2022
-$186.29M(-1159.4%)
-$54.64M(-38.2%)
-$186.29M(-17.5%)
Sep 2022
-
-$39.52M(-7.4%)
-$158.53M(-82.3%)
Jun 2022
-
-$36.81M(+33.5%)
-$86.94M(-99.2%)
Mar 2022
-
-$55.32M(-105.8%)
-$43.64M(-195.0%)
Dec 2021
-$14.79M(+65.4%)
-$26.88M(-183.8%)
-$14.79M(-728.7%)
Sep 2021
-
$32.06M(+393.6%)
-$1.78M(+93.4%)
Jun 2021
-
$6.50M(+124.5%)
-$27.11M(+32.3%)
Mar 2021
-
-$26.47M(-90.9%)
-$40.06M(+6.3%)
Dec 2020
-$42.74M(+26.6%)
-$13.87M(-305.9%)
-$42.74M(-28.1%)
Sep 2020
-
$6.74M(+204.4%)
-$33.37M(+38.5%)
Jun 2020
-
-$6.45M(+77.9%)
-$54.22M(+18.9%)
Mar 2020
-
-$29.16M(-549.0%)
-$66.88M(-14.9%)
Dec 2019
-$58.21M(-133.2%)
-$4.49M(+68.2%)
-$58.21M(-1.6%)
Sep 2019
-
-$14.12M(+26.1%)
-$57.29M(-21.7%)
Jun 2019
-
-$19.11M(+6.7%)
-$47.06M(-53.2%)
Mar 2019
-
-$20.49M(-474.8%)
-$30.72M(-23.1%)
Dec 2018
-$24.96M(-437.1%)
-$3.56M(+8.6%)
-$24.96M(-12.2%)
Sep 2018
-
-$3.90M(-41.3%)
-$22.25M(-83.1%)
Jun 2018
-
-$2.76M(+81.3%)
-$12.15M(-166.7%)
Mar 2018
-
-$14.73M(-1625.3%)
-$4.55M(-161.5%)
Dec 2017
$7.40M
-$854.00K(-113.8%)
$7.40M(+395.5%)
Sep 2017
-
$6.20M(+28.2%)
$1.49M(+3635.0%)
Jun 2017
-
$4.83M(+274.2%)
$40.00K(+105.0%)
DateAnnualQuarterlyTTM
Mar 2017
-
-$2.78M(+59.0%)
-$805.00K(+49.6%)
Dec 2016
-$1.60M(-188.1%)
-$6.76M(-242.6%)
-$1.60M(-161.0%)
Sep 2016
-
$4.74M(+18.9%)
$2.62M(+475.6%)
Jun 2016
-
$3.99M(+211.9%)
-$697.00K(-121.7%)
Mar 2016
-
-$3.57M(-39.9%)
$3.21M(+679.9%)
Dec 2015
-$554.00K(+98.8%)
-$2.55M(-278.4%)
-$554.00K(+92.2%)
Sep 2015
-
$1.43M(-81.9%)
-$7.10M(+70.5%)
Jun 2015
-
$7.90M(+207.7%)
-$24.03M(+44.6%)
Mar 2015
-
-$7.33M(+19.4%)
-$43.38M(+5.4%)
Dec 2014
-$45.85M(-160.7%)
-$9.09M(+41.3%)
-$45.85M(-2.1%)
Sep 2014
-
-$15.50M(-35.4%)
-$44.90M(-40.1%)
Jun 2014
-
-$11.45M(-16.8%)
-$32.06M(-40.5%)
Mar 2014
-
-$9.81M(-20.4%)
-$22.82M(-29.7%)
Dec 2013
-$17.59M(-542.7%)
-$8.15M(-206.8%)
-$17.59M(-86.3%)
Sep 2013
-
-$2.66M(-20.2%)
-$9.44M(-39.1%)
Jun 2013
-
-$2.21M(+51.8%)
-$6.79M(-48.2%)
Mar 2013
-
-$4.58M(>-9900.0%)
-$4.58M(>-9900.0%)
Dec 2012
-$2.74M(>-9900.0%)
-
-
Nov 2011
-
$0.00(0.0%)
-$600.00(+14.3%)
Aug 2011
-
$0.00(0.0%)
-$700.00(0.0%)
May 2011
-
$0.00(+100.0%)
-$700.00(0.0%)
Feb 2011
-$700.00(-600.0%)
-$600.00(-500.0%)
-$700.00(-600.0%)
Nov 2010
-
-$100.00(>-9900.0%)
-$100.00(>-9900.0%)
Aug 2010
-
$0.00(0.0%)
$0.00(+100.0%)
May 2010
-
$0.00(0.0%)
-$100.00(0.0%)
Feb 2010
-$100.00(+99.5%)
$0.00(0.0%)
-$100.00(0.0%)
Nov 2009
-
$0.00(+100.0%)
-$100.00(+66.7%)
Aug 2009
-
-$100.00(>-9900.0%)
-$300.00(-50.0%)
May 2009
-
$0.00(0.0%)
-$200.00(+99.0%)
Feb 2009
-$20.20K(>-9900.0%)
$0.00(+100.0%)
-$20.20K(0.0%)
Nov 2008
-
-$200.00(>-9900.0%)
-$20.20K(-1.0%)
Aug 2008
-
$0.00(+100.0%)
-$20.00K(0.0%)
May 2008
-
-$20.00K
-$20.00K
Feb 2008
$0.00
-
-

FAQ

  • What is Travere Therapeutics, Inc. annual cash from operations?
  • What is the all-time high annual cash from operations for Travere Therapeutics, Inc.?
  • What is Travere Therapeutics, Inc. annual cash from operations year-on-year change?
  • What is Travere Therapeutics, Inc. quarterly cash from operations?
  • What is the all-time high quarterly cash from operations for Travere Therapeutics, Inc.?
  • What is Travere Therapeutics, Inc. quarterly cash from operations year-on-year change?
  • What is Travere Therapeutics, Inc. TTM cash from operations?
  • What is the all-time high TTM cash from operations for Travere Therapeutics, Inc.?
  • What is Travere Therapeutics, Inc. TTM cash from operations year-on-year change?

What is Travere Therapeutics, Inc. annual cash from operations?

The current annual cash from operations of TVTX is -$237.47M

What is the all-time high annual cash from operations for Travere Therapeutics, Inc.?

Travere Therapeutics, Inc. all-time high annual cash from operations is $7.40M

What is Travere Therapeutics, Inc. annual cash from operations year-on-year change?

Over the past year, TVTX annual cash from operations has changed by +$42.55M (+15.19%)

What is Travere Therapeutics, Inc. quarterly cash from operations?

The current quarterly cash from operations of TVTX is $4.98M

What is the all-time high quarterly cash from operations for Travere Therapeutics, Inc.?

Travere Therapeutics, Inc. all-time high quarterly cash from operations is $32.06M

What is Travere Therapeutics, Inc. quarterly cash from operations year-on-year change?

Over the past year, TVTX quarterly cash from operations has changed by +$45.23M (+112.38%)

What is Travere Therapeutics, Inc. TTM cash from operations?

The current TTM cash from operations of TVTX is -$115.44M

What is the all-time high TTM cash from operations for Travere Therapeutics, Inc.?

Travere Therapeutics, Inc. all-time high TTM cash from operations is $7.40M

What is Travere Therapeutics, Inc. TTM cash from operations year-on-year change?

Over the past year, TVTX TTM cash from operations has changed by +$173.42M (+60.04%)
On this page